

## Humber Area Prescribing Committee

|                              |  |
|------------------------------|--|
| <b>Date / Time</b>           | 7 <sup>th</sup> August 2024 13:00-15:00  |
| <b>Venue</b>                 | MS Teams   |
| <b>Chair</b>                 | Dr Sergio Raise  |
| <b>Notes / Action Points</b> | Luke Storr – Senior Pharmacy Technician, HUTH                                    |
| <b>Quorate: Yes / No</b>     | No – JM contacted NP/AM/JG outside meeting and confirmed approved documentation. |

|                   |   |
|-------------------|---|
| <b>Attendance</b> | Dr Sergio Raise, ERY sub-locality GP Prescribing Lead (SR)<br>Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM)<br>Luke Storr – Senior Pharmacy Technician, HUTH (LS)<br>Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK)<br>Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB)<br>Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc)<br>Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK)<br>Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF)<br>Simon Priestley- Chief Pharmacist, NLAG (SP)<br>Natasha Suffill- Lead Clinical Pharmacist CHCP (NS)<br>Dr Pratik Basu- GP- The Birches medical practice (PB)<br>Jeeten Raghvani – GP- Greenlands Surgery (JR)<br>Catherine Smith- Senior Medicines Optimisation Pharmacist, NECS (CS) |
|-------------------|---|

|                  |   |
|------------------|---|
| <b>Apologies</b> | Daniel Newsome- Principal Pharmacist RDTC (DN) – PR sent in place<br>Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA)<br>Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH)<br>Joanne Goode – Chief Pharmacist – HUTH (JG)<br>Prof A Morice, Professor of Respiratory Medicine HUTH- (AM)<br>Dr Narayana Pothina- Consultant in adult medicine, NLAG (NP) |
|------------------|---|

| Agenda Number | Item                        | Discussion  | Action          | Lead     | Due Date |
|---------------|-----------------------------|---|-----------------|----------|----------|
| 2024.08.01    | Apologies                   | Noted above   |                 |          |          |
| 2024.08.02    | Declarations of interest    | Nil   |                 |          |          |
| 2024.08.03    | Minutes of previous meeting | Accepted as true record   |                 |          |          |
| 2024.08.04    | Action Tracker              | <p><b>Outstanding actions from NLAPC</b></p> <p>Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs)</p> <p>JM to provide RS information on number of patients in NEL/NL</p> <p>December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole</p> <p>February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL).</p> <p>March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update</p> <p>April update: Riluzole to JM to update websites to include NL</p> <p>May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review</p> <p>June update: Modafanil still waiting on NL, JM to review mycophenolate for July guideline group</p> <p>July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group</p> <p>August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group</p> <p>September 2023 update: For September guideline group</p> <p>October 2023 update: For November Guideline group</p> <p>November 2023 update: For November Guideline group</p> <p>December 2023 update: For January or March guideline group – to check against York mycophenolate.</p> | Action complete | JM/RS/CS | 8/24     |



|  |  |   |         |    |       |
|--|--|---|---------|----|-------|
|  |  | <p>August update: no further update, infliximab audit in HUTH started</p> <p>September update: HUTH audits still ongoing</p> <p>October update: HUTH audits still ongoing</p> <p>November update: HUTH audits still ongoing</p> <p>December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch.</p> <p>February 2024 update: Ustekinumab audit outcome form presented which demonstrated compliance with NICE guidance.</p> <p>March 2024 update: Infliximab paper due to presented at April D&amp;TC</p> <p>April 2024 update: HUTH D&amp;TC not until next week to update next time</p> <p>May 2024 update: Infliximab paper presented to HUTH D&amp;TC at last meeting alongside updated guidance (on agenda). HUTH infliximab IBD audit was presented to D&amp;TC and noted multiple dosage regimens are in use. Evaluated cost effectiveness versus current second line agents (vedolizumab or ustekinumab) and escalated infliximab is significantly more cost effective. This will be reviewed as more biosimilar agents become available.</p> <p>July 2024 update: for further discussion at HUTH D&amp;TC as compliance with NICE guidance for red drugs is an internal acute trust issue.</p> <p>August 2024 update: to close here. To add joint Humber Partnership Medicines and Therapeutics meeting agenda.</p> <p><b>Outstanding actions from HERPC:</b> Rheumatology to prepare pathway with rituximab without MTX</p> <p>August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&amp;TC action tracker. To discuss at September D&amp;TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper.</p> <p>September update: September D&amp;TC next week, further updates to pathway needed</p> <p>October update: Awaiting updated pathway</p> | Ongoing | JM | 10/24 |
|--|--|---|---------|----|-------|



|            |   |   |                     |          |      |
|------------|---|---|---------------------|----------|------|
|            |   | <p>March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG.</p> <p>April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements.</p> <p>June 2024 update – updated SCF on agenda</p> <p>July 2024 update – updated SCF on agenda</p> <p>August 2024 update – Comments from last meeting sent to CS, final version to be circulated when ready.</p> <p><b>Ratification of guidelines and SCFs</b><br/>To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance<br/>April 2024 update: ongoing<br/>May 2024: ongoing<br/>July 2024: ongoing</p> <p><b>Ratification of guidelines and SCFs</b><br/>To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded<br/>April 2024 update: ongoing<br/>May 2024: ongoing<br/>July 2024: ongoing</p> <p><b>Ratification of joint formulary</b><br/>Update joint formulary with chapter 3</p> <p><b>Ratification of joint formulary</b><br/>Update joint formulary with chapter 11</p> <p><b>Traffic Light Status</b><br/>To update formulary (netformulary) – action complete</p> <p><b>Traffic Light Status</b><br/>To update formulary (HERPC) - action complete</p> <p><b>Traffic Light Status</b><br/>To update red list (HERPC) - action complete</p> <p><b>RDTC updates</b><br/>To update netFormulary with NICE TAs</p> <p><b>Any other business</b><br/>Add sitagliptin to joint formulary agenda.</p> | Ongoing             | JM       | 4/24 |
|            |   |   | Ongoing             | JM       | 4/24 |
|            |   |   | Ongoing             | JM/LS/AK | 9/24 |
|            |   |   | Ongoing             | JM/LS/AK | 9/24 |
|            |   |   | Action complete     | JM/LS/AK | 8/24 |
|            |   |   | Action complete     | JM/LS/AK | 8/24 |
|            |   |   | Action complete     | JM/LS/AK | 8/24 |
|            |   |   | Action complete     | AK/JM    | 9/24 |
|            |   |   | Action complete     | LS       | 8/24 |
| 2024.08.05 | Traffic Light Status                                      | RSV vaccines- approved  | To update formulary | JM/LS/AK | 7/24 |
| 2024.08.06 | Feedback from Integrated Medicines Optimisation Committee | <ul style="list-style-type: none"> <li>• Atogepant- as funding movement needs approval at each of the placed.</li> <li>• Blood glucose monitoring- approved</li> <li>• Edoxaban and anticoagulants- work on making sure weights are up to date</li> </ul>   | Noted               |          |      |

|            |                                     |   |  |          |  |
|------------|-------------------------------------|---|--|----------|--|
|            |                                     | <ul style="list-style-type: none"> <li>• Topiramate MHRA drug safety update discussed.</li> </ul>   |  |          |  |
| 2024.08.07 | Work plans                          | <ol style="list-style-type: none"> <li>a) Joint formulary alignment</li> <li>b) Shared care frameworks</li> <li>c) Guidelines</li> </ol>  | Ongoing for information only   |          |  |
| 2024.08.08 | Ratification of joint formulary     | <ul style="list-style-type: none"> <li>• Nil this month</li> </ul>  |  |          |  |
| 2024.08.09 | Ratification of guidelines and SCFs | <ol style="list-style-type: none"> <li>a) Amiodarone SCF – amendments following comments from NEL/NL places. Not in enhanced services in NEL/NL; this to be addressed within current enhanced services discussions.</li> <li>b) Migraine (Amber guidance) – updated with information on topiramate safety, atogepant and chronic migraine pathway updated. To check links as stated a number not working and cannot be uploaded until atogepant funding resolved. Content approved.</li> <li>c) Prasugrel (Amber guidance) – reviewed guidance from HERPC guidance, updated onto new template. Addition of information on gastroprotection.</li> <li>d) Sublingual immunotherapy – reclassification changes reviewed however needs considering at NY&amp;Y APC as well. Funding would need reviewing as well. Guideline content approved however cannot be uploaded until discussed at NY&amp;Y APC. JM to send documentation to NY&amp;Y APC for review and comment.</li> <li>e) Ticagrelor 90mg– reviewed guidance from HERPC guidance, updated onto new template. Addition of information on gastroprotection.</li> <li>f) Iron deficiency pathway – extensive discussions on pathway, committee felt pathway needed more clarification prior to coming back to APC.</li> <li>g) Lipid guideline – reviewed guidance which has been updated with classification of bempedoic acid and new target ranges. The familial hypercholesterolaemia is currently undergoing updates and when completed will be added into the document (the current version will be linked in).</li> </ol> | <ol style="list-style-type: none"> <li>a) Approved, to upload</li> <li>b) To check links and upload when atogepant funding resolved</li> <li>c) Approved, to upload</li> <li>d) Approved</li> <li>e) Deferred- more work required</li> <li>f) Approved, to upload</li> </ol> | JM       |  |
| 2024.08.10 | RDTC updates                        | <ul style="list-style-type: none"> <li>• June 2024</li> </ul>   | Update formulary/red list  | JM/LS/AK |  |
| 2024.08.11 | Minutes from subcommittees          | <ol style="list-style-type: none"> <li>a) Joint formulary subcommittee (Nil)</li> <li>b) Guideline subcommittee (Nil)</li> </ol>  | Attached for info only   |          |  |

|                   |   |  |                        |  |  |
|-------------------|---|--|------------------------|--|--|
| <b>2024.08.12</b> | <b>Additional minutes for information</b> | a) HUTH D&TC (Nil)<br>b) HFT DTG (May 24)<br>c) NLAG M&T (June 24)<br>d) NYY APC (June 24) | Attached for info only |  |  |
| <b>2024.08.13</b> | <b>Correspondence received</b>            | Nil this month   |                        |  |  |
| <b>2024.08.14</b> | <b>AOB</b>                                |  |                        |  |  |
| <b>2024.08.15</b> | <b>Date of next meeting</b>               | 4 <sup>th</sup> September 2024 13.00 – 15.00 Teams   |                        |  |  |